OR WAIT null SECS
August 20, 2026
Article
A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.
August 10, 2026
Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.
July 28, 2026
The FDA has officially granted Fast Track designation to HTX-001 for the treatment of non-obstructive hypertrophic cardiomyopathy.
July 09, 2026
Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events in the phase 3 CARDIO-TTRansform trial.
July 06, 2026
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.
July 01, 2026
Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.
June 02, 2026
May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.
June 01, 2026
FDA accepted a priority review sNDA for mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.
May 08, 2026
Video
Ahmad Masri, MD, from OHSU, discusses the positive topline results from this phase 3 trial, highlighting a new path forward for nHCM.
May 04, 2026
April 2026 saw further updates from ACC.26, plus key trial results, guideline updates, and more.
